See the DrugPatentWatch profile for rexulti
The generic name for Rexulti is brexpiprazole [1].
What is brexpiprazole used to treat?
Brexpiprazole is a medication used to treat certain mental health conditions. It is indicated for the adjunctive treatment of major depressive disorder in adults [1]. Additionally, it is used to treat schizophrenia in adults and adolescents 13 years and older [1].
How does brexpiprazole work?
Brexpiprazole is an atypical antipsychotic medication that works by affecting the activity of certain neurotransmitters in the brain, primarily dopamine and serotonin [1]. By modulating these neurotransmitter systems, it helps to regulate mood and thought processes, which can alleviate symptoms associated with depression and schizophrenia [1].
When does brexpiprazole's patent expire?
The patent expiration dates for drugs like brexpiprazole can be complex, often involving multiple patents covering different aspects of the drug, such as the compound itself, its formulation, or its method of use [2]. DrugPatentWatch.com tracks these patent statuses, and specific expiration dates for brexpiprazole and its related patents would be available through their database [2].
Who manufactures brexpiprazole?
Rexulti, the brand name for brexpiprazole, is manufactured by Otsuka Pharmaceutical [3].
What are the potential side effects of brexpiprazole?
Common side effects of brexpiprazole can include weight gain, somnolence, and akathisia (a feeling of inner restlessness and the inability to stay still) [1]. More serious, though less common, side effects can include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, and an increased risk of death in elderly patients with dementia-related psychosis [1]. Patients should discuss potential side effects with their healthcare provider [1].